Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

CompletedOBSERVATIONAL
Enrollment

4,888

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2023

Conditions
Diabetes Mellitus, Type 2Renal Insufficiency, Chronic
Interventions
DRUG

Metformin

Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider

DRUG

Sulfonylurea

Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider

DRUG

DPP-4 inhibitor

Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider

DRUG

SGLT2 inhibitor

Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider

DRUG

GLP1 receptor agonist

Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider

Trial Locations (2)

27599

University of North Carolina, Chapel Hill

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Weill Medical College of Cornell University

OTHER

NCT03921242 - Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter